A significant improvement in the median overall survival in patients with metastatic colorectal cancer was achieved when Bevacizumab (a monoclonal antibody directed against the tyrosine kinase receptor, VEGF) was added to a chemotherapy regimen of oxaliplatin and 5-fluorouracil (P = 0.0024) [3]. The gene discussed is NTRK1; the disease is metastatic colorectal cancer.